Background Cardiovascular disease is a major cause of morbidity and mortality in people
living with HIV, who are at higher risk than the general population. We assessed, in a large …

BACKGROUND People living with HIV (PLHIV) receiving antiretroviral therapy (ART) exhibit
persistent immune dysregulation and microbial dysbiosis, leading to development of …

Introduction Immunological non-responders (INR) are people living with HIV (PLHIV) who
fail to fully restore CD4+ T-cell counts despite complete viral suppression with antiretroviral …

Background Insights into the mechanisms driving metabolic dysfunction-associated steatotic
liver disease (MASLD) in people living with HIV (PLHIV) remain limited. Plasma proteomics …

In people living with HIV (PLHIV), integrase strand transfer inhibitors (INSTIs) are part of the
first-line combination antiretroviral therapy (cART), while non-nucleoside reverse …

Acquired immunodeficiency syndrome (AIDS) has transitioned from a progressive, fatal
disease to a chronic, manageable disease thanks to better defining of antiretroviral therapy …

Background Steatotic liver disease is suggested to have a higher prevalence and severity in
people with HIV (PHIV), including in those with a normal body mass index (BMI). In this …

Acquired immunodeficiency syndrome (AIDS) has transitioned from a progressive, fatal
disease to a chronic, manageable disease thanks to better defining of antiretroviral therapy …

In people living with HIV (PLHIV), integrase strand transfer inhibitors (INSTIs) are part of the
first-line combination antiretroviral therapy (cART), while non-nucleoside reverse …

Antiretroviral therapy (ART) reduces viral replication, restores T helper cells and improves
the survival of people living with HIV (PWH), transforming a life-threatening disease into a …